Galapagos News

102,45 +0,49% +0,50 €
23.04.19 15:40:57 Uhr Frankfurt | Orderbuch | Mehr Kurse »
WKN: A0EAT9
ISIN: BE0003818359
US-Symbol: GLPGF
Typ: Aktie

Galapagos News

  
10.04.19 Galapagos creates new warrant plans GlobeNewswire
29.03.19 Publication of the annual report and invitation to the annual shareholders' meeting GlobeNewswire
28.03.19 GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) GlobeNewswire
28.03.19 GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) GlobeNewswire
28.03.19 GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY ENDPOINT IN THE PHASE 3 FINCH 3 STUDY IN METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS GlobeNewswire
28.03.19 GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY GlobeNewswire
20.03.19 Galapagos increases share capital through warrant exercises GlobeNewswire
21.02.19 Firmly on our way to becoming a fully integrated biopharma company GlobeNewswire
07.02.19 Evotec gelingt neuer Deal - kommt nun das Kaufsignal? Der Aktionär
07.02.19 Evotec and Galapagos enter into collaboration in the field of fibrosis GlobeNewswire
21.01.19 Galapagos Aktie 2019 Finanztrends
08.01.19 Sands Capital reports 5.7% holding in Galapagos GlobeNewswire
07.01.19 Galapagos starts first Phase 1 trial with Toledo compound GlobeNewswire
06.01.19 Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis GlobeNewswire
04.01.19 Fibrocor and Galapagos sign partnership in fibrosis GlobeNewswire
21.12.18 Galapagos to Present at 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
17.12.18 Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF) GlobeNewswire
27.11.18 Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis GlobeNewswire
26.11.18 Transparency notification GlobeNewswire
23.11.18 Galapagos increases share capital through warrant exercises GlobeNewswire
31.10.18 Galapagos reports initiation of PINTA Phase 2 trial with GLPG1205 in patients with Idiopathic Pulmonary Fibrosis (IPF) GlobeNewswire
24.10.18 Galapagos and AbbVie restructure CF collaboration GlobeNewswire
24.10.18 Topline interim results of FALCON trial Part 1 in CF GlobeNewswire
24.10.18 Hallmark third quarter 2018 and Annual R&D Update at Galapagos GlobeNewswire
22.10.18 POSITIVE TRIAL RESULTS WITH FILGOTINIB IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS BOTH PUBLISHED IN THE LANCET GlobeNewswire
21.10.18 PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-​EXPERIENCED RHEUMATOID ARTHRITIS TO BE PRESENTED AT 2018 ACR/ARHP ANNUAL MEETING GlobeNewswire
03.10.18 Galapagos increases share capital through warrant exercises GlobeNewswire
24.09.18 Galapagos reports initiation of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in osteoarthritis patients GlobeNewswire
17.09.18 Galapagos issues new shares as result of public offering GlobeNewswire
17.09.18 Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €296.2 million GlobeNewswire
13.09.18 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106 GlobeNewswire
13.09.18 Morphosys erhält grünes Licht: Deal mit Novartis fix - jetzt einsteigen? Der Aktionär
13.09.18 Galapagos raises $300 million gross proceeds in a U.S. public offering GlobeNewswire
12.09.18 Galapagos announces launch of proposed public offering GlobeNewswire
12.09.18 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner GlobeNewswire
11.09.18 GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN FIRST PHASE 3 STUDY IN RHEUMATOID ARTHRITIS GlobeNewswire
06.09.18 GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ENDPOINT GlobeNewswire
03.08.18 Morphosys-​Aktie: Basisinvestment mit Höhenflug Börse Online
02.08.18 Productive first half-year at Galapagos GlobeNewswire
19.07.18 Hammer-​Deal für Morphosys und Galapagos: Novartis steigt bei MOR106 ein Der Aktionär
19.07.18 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner GlobeNewswire
09.07.18 Galapagos announces design for PINTA Phase 2 trial with GLPG1205 in IPF GlobeNewswire
29.06.18 BB-​Biotech-Beteiligung Vertex +8%: Probleme beim Rivalen Galapagos Der Aktionär
26.06.18 Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis patients GlobeNewswire
20.06.18 Galapagos increases share capital through warrant exercises GlobeNewswire
14.06.18 Transparency notification GlobeNewswire
30.05.18 GILEAD AND GALAPAGOS ANNOUNCE RESULTS WITH FILGOTINIB IN THE PHASE 2 EQUATOR STUDY IN PSORIATIC ARTHRITIS AND PROGRESSION INTO PHASE 3 FOR THE SELECTION STUDY IN ULCERATIVE COLITIS GlobeNewswire
22.05.18 Gilead-​Partner Galapagos und Fibrogen: Hot-​Stocks im Aufwind - die Hintergründe Der Aktionär
20.05.18 GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS GlobeNewswire
02.05.18 Morphosys ganz knapp vor Mega-​Kaufsignal - Partnerprojekt läuft erfolgreich Der Aktionär

Newssuche